Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares rose 8.5% during trading on Friday . The stock traded as high as $1.43 and last traded at $1.41. Approximately 2,127,498 shares traded hands during mid-day trading, an increase of 219% from the average daily volume of 666,314 shares. The stock had previously closed at $1.30.

TTPH has been the topic of several analyst reports. Robert W. Baird reaffirmed a “buy” rating and issued a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday, January 7th. B. Riley initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Friday, January 4th. They issued a “buy” rating and a $3.00 target price on the stock. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 23rd. Piper Jaffray Companies decreased their target price on shares of Tetraphase Pharmaceuticals from $6.00 to $4.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Gabelli downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and an average target price of $4.54.

The company has a market capitalization of $75.61 million, a P/E ratio of -0.54 and a beta of 2.99.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Thursday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.40). The business had revenue of $4.28 million for the quarter, compared to the consensus estimate of $2.23 million. Tetraphase Pharmaceuticals had a negative net margin of 432.40% and a negative return on equity of 65.89%. As a group, equities research analysts expect that Tetraphase Pharmaceuticals Inc will post -1.39 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the business. Paloma Partners Management Co purchased a new position in Tetraphase Pharmaceuticals during the 4th quarter valued at $33,000. Gamco Investors INC. ET AL increased its position in Tetraphase Pharmaceuticals by 42.9% during the 4th quarter. Gamco Investors INC. ET AL now owns 50,000 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 15,000 shares during the period. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the 4th quarter valued at $69,000. Rhumbline Advisers increased its position in Tetraphase Pharmaceuticals by 40.6% during the 4th quarter. Rhumbline Advisers now owns 72,976 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 21,089 shares during the period. Finally, Alambic Investment Management L.P. increased its position in Tetraphase Pharmaceuticals by 392.6% during the 3rd quarter. Alambic Investment Management L.P. now owns 87,704 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 69,900 shares during the period. 44.12% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Tetraphase Pharmaceuticals (TTPH) Stock Price Up 8.5%” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.watchlistnews.com/tetraphase-pharmaceuticals-ttph-stock-price-up-8-5/2897139.html.

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Read More: What is Compound Interest?

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.